Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas-Reference-Cited by-同舟云学术

Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas

Published:2023-05-31 Issue:8 Volume:64 Page:1424-1432
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ribereau-Gayon Emmanuel¹²^ORCID,Donzel Marie³,Pham Felix¹,Romain-Scelle Nicolas⁴,Perier-Muzet Marie¹,Balme Brigitte³,Traverse-Glehen Alexandra³,Ghesquières Hervé⁵,Dalle Stéphane¹

Affiliation:

1. Service de Dermatologie, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France

2. Université Claude Bernard Lyon 1, Lyon, France

3. Hospices Civils de Lyon, Hôpital Lyon Sud, Service de Pathologie, Pierre Bénite, France

4. Hospices Civils de Lyon, Hôpital Lyon Sud, Service de Santé Publique, Pierre Bénite, France

5. Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’Hématologie, Pierre Bénite, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2216820

Reference41 articles.

1. WHO-EORTC classification for cutaneous lymphomas

2. Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma

3. Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

4. A review of CD30 expression in cutaneous neoplasms

5. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T-cell lymphoma: long-term remission after brentuximab vedotin

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin;Journal of Clinical Medicine;2024-01-31

2. Rechallenge of brentuximab vedotin was effective for refractory mycosis fungoides: a case report;Journal of Cutaneous Immunology and Allergy;2024-01-25